Welcome to our dedicated page for Affimed SEC filings (Ticker: AFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Affimed’s SEC filings do more than tally numbers—they trace how its ROCK® platform and innate cell engager programs move from lab to clinic. Yet decoding trial cohorts, milestone payments, or dilution from ATM financings inside a 300-page 10-K can drain hours. Investors asking “What does Affimed report in its SEC filings?” or trying to spot “Affimed insider trading Form 4 transactions” often end up sifting through footnotes instead of insights.
Stock Titan solves that problem. Our AI delivers “Affimed SEC filings explained simply,” turning each quarterly document into a concise briefing. Get alerts the moment an “Affimed 8-K material events explained” hits EDGAR, review the latest “Affimed quarterly earnings report 10-Q filing,” and dive into an “Affimed annual report 10-K simplified” summary that highlights cash runway and clinical trial spend. Real-time feeds surface “Affimed Form 4 insider transactions real-time” so you can watch “Affimed executive stock transactions Form 4” without refreshing the SEC site.
Need granular detail? Click straight to pipeline disclosures, collaboration revenue breakouts, or “Affimed proxy statement executive compensation” tables—each section paired with an “Affimed earnings report filing analysis” crafted by AI and validated by sector experts. From underwriting agreements to shelf registrations, every document is indexed, searchable, and updated instantly, so understanding Affimed SEC documents with AI becomes part of your routine research workflow.
Nasdaq Stock Market LLC has filed Form 25 to strike Affimed N.V. (AFMD) common stock from listing and registration under Section 12(b) of the Exchange Act. The notification, signed on 2025-07-21 by a Nasdaq hearings advisor, states that the exchange believes it meets all regulatory requirements for delisting. No financial results, trading data, or rationale are provided in the filing.
The action will remove AFMD from the Nasdaq Global Market once the SEC’s 10-day period elapses, and registration under Section 12(g) will be terminated after 90 days unless the company files contrary documentation. Investors should anticipate the stock moving to an over-the-counter venue or another exchange, subject to separate listing standards.
FAQ
What is the current stock price of Affimed (AFMD)?
What is the market cap of Affimed (AFMD)?
What is the primary focus of Affimed N.V.?
How does Affimed's technology work?
What products or therapies are in Affimed's pipeline?
How does Affimed generate revenue?
What distinguishes Affimed from its competitors?
In which markets does Affimed operate?
What are the advantages of the company’s tetravalent antibody architecture?
How does Affimed contribute to advancing immuno-oncology?
